Author of

• 17493

  +

  P2.02 - Poster Session with Presenters Present (ID 462)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Locally Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17534

    +

    P2.02-041 - The Impact of Surgical Resection after Concurrent Chemotherapy and High Dose (61 Gy) Radiation in Stage IIIA/N2 Non-Small Cell Lung Cancer (ID 6304)

    14:30 - 14:30  |  Author(s): G. Aydin
    • Abstract

    Background:
    Locally advanced stage IIIA non-small-cell lung cancer with N2 disease is the most advanced stage at which cure can be achieved, but more than 60% of patients eventually die from their disease. For patients with stage IIIA/N2 disease, two standard treatment options are offered: definitive concurrent chemoradiotherapy or surgery combined with chemo/radiotherapy. We aimed to investigate the role of surgery after concurrent chemoterapy and high dose radiation in patients with N2 disease.
    
    Methods:
    Between January 2011 and December 2015 eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer and were prospectively recorded. Those in the chemoradiotherapy group received three cycles of neoadjuvant chemotherapy (AUCx2 carpoplatin and docetaxel 85 mg/m[2 ] docetaxel) and concurrent radiotherapy with 61.2 Gy in 34 fractions over 3 weeks followed by surgical resection, and those in the control group received definitive chemoradiotherapy alone. All patients in two groups were proven to have no N2 disease after chemoradiotherapy.
    
    Results:
    A total of 58 patients were enrolled, of whom 21 received chemoradiotherapy followed by surgical resection and 37 had chemoradiotherapy only. Median overall survival was 35 months (95% CI 10.5–44.0) in the chemoradiotherapy + surgery group and 20.3 months (4.5–38.6) in the chemotherapy group (p=0.03). Median overall survival was 37·1 months (95% CI 22·6–50·0) with radiotherapy, compared with 26·2 months (19·9–52·1) in the control group. One patients died in the surgery group within 30 days after surgery.
    
    Conclusion:
    Pulmonary resection after high-dose neoadjuvant chemoradiotherapy is safe and surgical resection after chemoradiotherapy may provide better survival in histologically proven N2 stage IIIA non-small cell lung cancer.